Amoxicillin and clavulanate potassium pharma-grade API is a two-component active substance system prepared from amoxicillin trihydrate (CAS 61336-70-7) and clavulanate potassium (CAS 61177-45-5) for the manufacture of immediate-release tablets, hard gelatin capsules, oral dry granules/suspension, and sterile injectable dosage forms. The product is defined by compendial grade rather than a proprietary model number: amoxicillin trihydrate must comply with the current USP-NF Amoxicillin monograph and the corresponding Ph. Eur. monograph, while clavulanate potassium must comply with the current USP-NF Clavulanate Potassium monograph and the corresponding Ph. Eur. monograph. Typical fixed ratios for solid oral dosage manufacture are 2:1, 4:1, 7:1, and 8:1 amoxicillin:clavulanic acid, expressed on the free acid equivalent; injectable grade is commonly 5:1 using amoxicillin sodium and clavulanate potassium. The presence of clavulanate potassium differentiates the product from amoxicillin trihydrate alone by irreversibly inhibiting Ambler class A beta-lactamases, including TEM-1, SHV-1, and several extended-spectrum variants, thereby restoring amoxicillin activity against many beta-lactamase-producing organisms. The API is not a simple blend of two powders; it requires separate release of each active substance and, when supplied as a co-processed mixture, verification of ratio uniformity, particle-size distribution, moisture uptake, and degradation behavior.

What Compendial and GMP Controls Apply to This Combination API?

Because no harmonized fixed-dose combination API monograph exists, the two active substances are released separately under their respective monographs and then blended or co-processed under ICH Q7. Manufacturers of finished dosage forms should request batch-level data for assay, related substances, water content, residual solvents, elemental impurities, particle-size distribution, and powder-flow parameters. Table 1 summarizes typical compendial and process-control parameters. Limits for amoxicillin trihydrate assay are 900–1050 µg/mg on the anhydrous basis per the USP monograph; clavulanate potassium assay is generally 750–850 µg/mg of clavulanic acid. Water content of amoxicillin trihydrate is typically 11.5–14.5% by Karl Fischer titration, while clavulanate potassium is controlled at ≤1.5% because higher moisture accelerates hydrolytic degradation. Residual solvent control follows ICH Q3C, and elemental impurity control follows ICH Q3D. Microbiological quality for non-sterile oral API includes USP <61> and USP <62>; sterile injectable grade additionally requires bacterial endotoxin testing per USP <85> and sterility per USP <71>. For impurity control, reporting thresholds for a maximum daily dose above 2 g follow ICH Q3A: reporting threshold 0.05%, identification threshold 0.10%, and qualification threshold 0.15%. For clavulanate potassium, hydrolysis-related impurities include pyrazoline and desclavulanic acid analogues; their limits are stated in the individual monograph and should not be interpolated from amoxicillin impurity profiles.

When Direct Compression Is Not Feasible and Dry Granulation Is Required

Amoxicillin trihydrate and clavulanate potassium blends are not automatically suitable for direct compression. Clavulanate potassium is highly hygroscopic, and its particle size, bulk density, and flow function coefficient may differ from amoxicillin trihydrate, leading to segregation during hopper discharge and die filling. For direct compression, a target blend flowability corresponding to Carr index ≤25 and Hausner ratio ≤1.35 is often specified, but published data for this specific configuration is limited. In roller compaction, hydraulic pressure is typically adjusted in the range of 40–120 bar depending on roll diameter, roll speed, and screen granulator speed. Higher compaction pressure densifies the ribbon and improves flow but can convert clavulanate potassium to amorphous form on particle surfaces and increase moisture uptake. This creates a process conflict: the same mechanical energy that improves flow can reduce chemical stability. Therefore dry granulation of amoxicillin/clavulanate formulations is commonly conducted at controlled relative humidity below 40% RH, with inline temperature monitoring and rapid sealing of granulated materials into polyethylene-lined fiber drums containing desiccant. Excessive fines after milling can increase specific surface area and accelerate clavulanate hydrolysis; sieve revalidation is part of process qualification.

Compression speed and pre-compression force may need adjustment because clavulanate potassium can cause sticking to punch faces at residual moisture above 1.5%. Some manufacturers use external lubrication systems to minimize the amount of magnesium stearate, because hydrophobic lubricants at levels above 0.5% can retard amoxicillin dissolution. The choice of filler is constrained by incompatibility with primary or secondary amines; nucleophilic additives can open the beta-lactam ring and reduce potency. If a formulation requires wet granulation, non-aqueous granulation or spray granulation with rapid drying is used, but aqueous wet granulation is generally avoided because clavulanate potassium hydrolysis follows pH-dependent pseudo-first-order kinetics with a strong increase in rate above pH 6 and above 25°C. Powder-flow parameters are measured by USP <1174>, and bulk/tapped density is measured by USP <616> or Ph. Eur. 2.9.34.

Oral granule and dry suspension processes impose further constraints because the dose form is reconstituted by the patient or caregiver. The API blend must deliver a stable suspension after reconstitution with potable water; therefore the formulation includes suspending agents, buffers, and may include a desiccant in the package. Clavulanate potassium hydrolysis in reconstituted suspension follows first-order kinetics at 2–8°C; typical storage is 7 days under refrigeration, and manufacturers set in-use stability endpoints based on assay retention of not less than 90% of label claim. Particle-size control by laser diffraction per USP <429> is relevant because coarse amoxicillin trihydrate particles can cause gritty mouthfeel, while extremely fine particles may increase dissolution rate but reduce flow. For dry syrups and sachets, sieve fractions are often controlled at ≤10% retained on 250 µm and ≥70% passing 180 µm, depending on the delivery device and reconstitution volume. Taste masking is a formulation concern, but the API supplier’s specification is limited to chemical and physical attributes; sensory acceptability is established during finished product development.

Injectable-Grade Amoxicillin Sodium and Clavulanate Potassium

For injectable manufacture, the active substances are amoxicillin sodium and clavulanate potassium, not amoxicillin trihydrate. The conversion to sodium salt increases aqueous solubility and changes the lyophilization or sterile powder filling behavior. The API must be low in particulate matter, low in endotoxin, and compatible with primary packaging. Sterile powder fill lines require control of environmental humidity below 30% RH for clavulanate potassium because the substance is deliquescent at high humidity. The use of isolator or restricted access barrier systems is standard for sterile API dispensing. The route of administration makes the absence of pyrogens critical; therefore bacterial endotoxin limits are established per product monograph and are commonly in the range of ≤0.25 EU/mg for injectable beta-lactam powders, although the final limit must be justified by the finished product monograph. Sub-visible particulate limits per USP <789> for small-volume injections and USP <788> for large-volume infusions apply after reconstitution. Organic impurities are tightly controlled because degradation products such as dimeric and polymeric amoxicillin species may be associated with immunogenic reactions. HPLC methods per USP <621> typically include gradient elution to separate amoxicillin penicilloic acid, penilloic acid, amoxicillin dimer, and clavulanate-related degradation products. The API manufacturer must provide stability data under 25°C/60% RH and 40°C/75% RH to support transport and storage.

Compatibility with intravenous diluents and co-administered drugs must be verified in development. Penicillins are incompatible with aminoglycosides in the same container because acylation of the aminoglycoside amino groups can inactivate both compounds. Reconstitution with water for injection or a compendial diluent should follow the finished product monograph; pH, clarity, and particulate count after reconstitution are release parameters for the sterile powder fill line. Moisture ingress through stoppers and seals should be excluded by container-closure integrity testing, because clavulanate potassium degradation can occur even in sealed vials if headspace humidity is not controlled below the critical water activity.

The Comparative Spectrum Differs From Amoxicillin Monotherapy and Other Combinations

The presence of clavulanate potassium changes the susceptibility profile relative to amoxicillin monotherapy. Amoxicillin alone is destroyed by class A beta-lactamases; clavulanate potassium acylates the active-site serine and inactivates the enzyme. This does not confer activity against organisms expressing AmpC beta-lactamases, carbapenemases, or those with reduced outer membrane permeability. The combination is therefore not interchangeable with piperacillin–tazobactam or ampicillin–sulbactam. Table 2 summarizes differences relevant to formulation and microbiological target selection. Ampicillin–sulbactam contains sulbactam, which inhibits class A beta-lactamases but also has intrinsic activity against Acinetobacter baumannii; clavulanate potassium has weak intrinsic antibacterial activity. Amoxicillin/clavulanate oral ratios are typically 2:1, 4:1, 7:1, and 8:1, while ampicillin–sulbactam is frequently 2:1 ampicillin:sulbactam. For the API formulator, the main difference from amoxicillin trihydrate alone is the need to protect clavulanate potassium from moisture and heat during all unit operations.